RxDoctor Payments Data

Atalie Lapid, MD

Family Medicine · San Antonio, TXNPI 1407016918

Payments from drug & device makers

$774in general payments, 2019–2025

Across 47 payments — averaging $16.46 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$181
  • GSK$133
  • Ultragenyx Pharmaceutical Inc.$68
  • Johnson & Johnson$58
  • Lilly USA, LLC$54
  • Biomarin Pharmaceutical Inc.$43
  • plus $237 from 10 others

What the payments were for

  • Food & beverage$774100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$774 in reported general payments places this provider in the 55th percentile of 8,760 family medicine providers in Texas.

See all family medicine providers in Texas

Medicare billing

Part B allowed, 2024
$19,330
Medicare patients
66
Services billed
199

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide347$415,863
MounjaroTirzepatide103$114,891
TrulicityDulaglutide55$67,307
EliquisApixaban47$66,744
JardianceEmpagliflozin35$55,173
Tresiba Flextouch U-200Insulin Degludec23$30,305
Toujeo Max SolostarInsulin Glargine,hum.Rec.Anlog15$28,766
Toujeo SolostarInsulin Glargine,hum.Rec.Anlog20$27,738
Victoza 2-PakLiraglutide20$27,118
EntrestoSacubitril/Valsartan20$26,977
Trelegy ElliptaFluticasone/Umeclidin/Vilanter27$24,845
XareltoRivaroxaban16$21,839
Lantus SolostarInsulin Glargine,hum.Rec.Anlog106$16,463
Breo ElliptaFluticasone/Vilanterol31$15,139
Novolog FlexpenInsulin Aspart39$13,949

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$181$415,863347 claims
Lilly USA, LLCMounjaro, Trulicity$54$182,198158 claims
GSKTrelegy Ellipta, Breo Ellipta, Anoro Ellipta$133$51,03674 claims
Johnson & JohnsonXarelto$58$21,83916 claims
AstraZenecaBrilinta$35$8,41113 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 55th percentile of 8,760 family medicine providers in Texas.

Other family medicine in San Antonio

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →